Press Releases from Dr. Holger Bengs Biotech Consulting (13 total)
IonGate starts commercialization of SURFE2R in Asia
Frankfurt/Main, Germany, March 12, 2008. IonGate Biosciences is expanding its operations to market the SURFE2R (SURFace Electrogenic Event Reader) Technology to the Japanese market. BRC - Bio Research Center Co. Ltd Nagoya, Japan and IonGate jointly introduce the proprietary technique to automatically screen transport proteins in high throughput at meetings in Japan, thus making the technology accessible to the Asian market.
BRC is an established partner able to supply Japan’s researchers…
IonGate presents SURFE2R Technology and relevant fields of application at Biophy …
Frankfurt/Main (Germany), January 28, 2008. IonGate Biosciences GmbH will present its SURFE2R Technology for label-free and automatic measurement of transport proteins at the 52nd Annual Meeting and 16th International Biophysics Congress. The joint meeting of the American Biophysical Society takes place in Long Beach, California, USA, on February 2 – 6, 2008. Scientists from industry, universities and private academic institutes use this opportunity to present results of their latest research…
IonGate completes third funding round and expands its business to the USA
Frankfurt/Main (Germany), 16th January 2008. IonGate Biosciences GmbH announces the closing of the third funding round. The capital contribution of the investors Heidelberg Innovation and KfW (Kreditanstalt für Wiederaufbau) therewith amounts to €4.6 million in 2007. IonGate will use the increase in capital to expand its international business activities, for the worldwide commercialization of the SURFE2R Technology (SURFace Electrogenic Event Reader) and for the further development of the SURFE2R Workstation.
In…
Protagen raises €1 million to expand its protein biochips business unit
Dortmund, Germany and New Jersey, USA, 15 January 2008: Protagen AG, a leading provider of products, services and software solutions for protein research, announces the closing of an interim financing round. The €1 million raised will be used to expand the company’s protein biochips business unit.
The capital raised in this round has come from the existing institutional investors, MIG AG and Co KG Beteiligungsfonds 3, Munich, and S-Venture Capital Dortmund…
Protagen and Tomy Digital Biology announce distribution agreement for Modiro™ …
Agreement provides access to software for analysing post-translational modifications in Asia
Dortmund, 11 December 2007 - Protagen AG, a leading provider of products, services and software solutions for protein research, announced today that it has entered into a distribution agreement for its Bio-IT software product, Modiro™ – the PTM-Explorer with Tomy Digital Biology Co. Ltd of Tokyo, Japan.
Modiro™ was launched in the market in March this year, and the initial sales…
IonGate wins the Contest “365 Landmarks in the Land of Ideas”
Frankfurt/Main (Germany), 26th November 2007. IonGate Biosciences GmbH was elected by the initiative “Germany - Land of Ideas” as landmark in 2008. The motto “Surfing into the world of drugs” received the jury’s acclaim. IonGate will open it\'s doors to the public on November 17th 2008 and celebrate the award with an open day, offering visitors the rare opportunity to explore a highly innovative biotech company. A comprehensible program will…
IonGate sells SURFE2R Technology for the first time overseas
Frankfurt/Main (Germany), 2nd November, 2007. IonGate Biosciences GmbH announces an excellent start into the worldwide marketing of its SURFE2R Technology. Already established in Europe, it has now entered the North American market. In September the Department of Biochemistry and Molecular Biology at the University of Calgary, in Canada, purchased a SURFE2R One for research on transport proteins. In just a few weeks Prof. Jonathan Lytton, Professor in the Department and…
IonGate Biosciences and LIVC Technologies establish a technology and marketing c …
Frankfurt/Main (Germany), 3rd September 2007. IonGate Biosciences GmbH and LIVC Technologies GmbH, both located in Frankfurt am Main, Germany, today announced a co-operation for joint development and marketing of the LIVC Technology. LIVC is a proprietary technology that can initiate and measure voltage activated ion channels via light induction, which works similar to a remote control. This technology ensures high precision and high-throughput with maximum flexibility.
Until now, high-throughput activation and…
Neurotune expands its management by taking on an expert for preclinical developm …
Schlieren, 1st August 2007. Neurotune AG has taken on Dr. Jan Willem Vrijbloed for the expansion of its preclinical development division, and has appointed Michael Kregar as the new Chief Financial Officer (CFO).
As the director of preclinical and clinical development, Dr. Jan Willem Vrijbloed will be responsible for the development of new medications. Dr Vrijbloed, was born in 1960 in the Netherlands and has more than 15 years of experience…
IonGate automates active substance research on transporters with SURFE2R Worksta …
Frankfurt/Main (Germany), 31st July 2007. IonGate Biosciences GmbH announces the market launch of SURFE2R Workstation. For the first time a workstation allows a highly automated and efficient drug research on transporters and ion channels.
With this SURFE2R Workstation, IonGate provides the next automated device generation after SURFE2R One and the first to measure 96 sensor array plates. It is especially conceived for applications with higher throughput in pharmaceutical drug screening. Robust…
Neurotune AG is honoured on the occasion of the award ceremony „ZKB Pioneer Aw …
Schlieren, June 19th 2007. Neurotune AG was awarded a prize for its activity in the area of developing drugs to treat age-related muscle atrophy – Sarcopenia – and other disorders of the human nervous system on Tuesday evening.
Dr. Andreas J. Schulze, CEO of Neurotune, and Prof. Peter Sonderegger, CSO of Neurotune, received the award from Dr. Thomas von Waldkirch, President of the Foundation Board of TECHNOPARK® Zurich. In his…
Protagen expands Supervisory Board to support the development and commercialisat …
New Jersey, USA and Dortmund, Germany 6 June 2007 – Protagen AG, a leading provider of products, services and software solutions for protein research, has appointed Professor Theodor Dingermann to its Supervisory Board. Prof. Dingermann has been Managing Director of the Institute for Pharmaceutical Biology, at the Johann Wolfgang Goethe-University, Frankfurt-am-Main since 1991. His extensive experience in pharmaceutical research and development will support Protagen in its development and commercialisation of…
Protagen and ZAP partner with Kangdi Antibody Biotech and Bejing Proteome Resear …
Dortmund, Germany and Chester, NJ, US - 16th May 2007. Protagen AG, a leading provider of products, services and software solutions for protein research, has entered into an international collaboration to develop antibodies against liver proteins. Protagen announced it’s partnership with the Centre for Applied Proteomics (ZAP), Dortmund, Schunde Kangdi Antibody Biotech, Foshan, China and the Beijing Proteome Research Centre (Beijing PRC) today at the interna¬tional symposium on High Performance…
